Background -Currently available nebulisers are inefficient and show variable aerosol deposition in the lung owing to the differences in the particle size generated.
with an improvement in some parameters of bronchodilator efficacy. As a consequence of improved delivery with the Ventstream, it may be possible to halve the drug dose to produce similar bronchodilator efficacy at reduced cost. Further studies are required to evaluate the value of the Ventstream for delivery of nebulised antibiotics and corticosteroids. Currently available nebulisers lack precision in that a substantial proportion of the inhaled dose is lost to the atmosphere.' Furthermore, significant differences in lung deposition of aerosol can occur with commonly used nebuliser delivery systems as a result of variability in the particle size generated.23 Nebulisers remain widely accepted as the delivery system of choice, however, in those patients with chronic asthma or chronic obstructive pulmonary disease (COPD) who require high dose inhaled bronchodilator therapy.45 In contrast to metered dose and dry powder devices, there are relatively few available data regarding doseresponse relationships for nebulised bronchodilator drugs in either asthma or COPD' despite concerns regarding the systemic adverse effects of high dose inhaled agonists.
In this respect a novel nebuliser delivery system ("Ventstream", Medic-Aid, Pagham, UK) has been developed which improves delivery of inhaled drugs to the lungs using a low resistance one way valve system which allows a side flow in addition to the 6 1/min from the compressor source ( fig 1A) . This works by using the patient's own inspiration to boost the nebuliser performance during this phase of the respiratory cycle so that aerosol production matches the patient's tidal volume ( fig 1B) . Furthermore, on expiration the one way valves within the system only allow aerosol production to be generated from the compressor gas source which minimises drug wastage spectively at a concentration of 7-5 ng/ml. The limit of detection for the assay was 1 0 ng/ml.
The electrocardiogram was recorded on standard lead II using a Hewlett Packard (Palo Alto, California, USA) monitor and printer with paper speed set at 50 mm/s and 0 5 mV/cm gain. The following parameters were measured from the mean of five consecutive complexes: R-R interval (s), Q-T interval (ms), and T wave amplitude (mV). The Q-T interval was measured using the method described by Shamroth'2 to account for the presence of U waves. The formula of Bazett'3 was used to correct the Q-T interval for heart rate (Q-Tc). The heart rate was calculated from the R-R interval.
Finger tremor was recorded by a previously validated method'4 using an accelerometer transducer (Entran Ltd, Ealing, UK); five recordings were taken and stored on computer disk for subsequent spectral analysis of total tremor power >2 Hz (units of mg2/s) using computer assisted autocovariance. The mean of the three lowest consistent readings was used. Since tremor power is not normally distributed, log transformation was used in the analysis. (ii) Delta response (table 3): There were no significant differences between the 1-25 mg and 2 5 mg doses for either nebuliser. There were significant differences (p<005) between the 2 5 mg and 5 0 mg doses for all systemic responses except for Q-Tc when using the Ventstream, and a significant (p<005) difference in serum potassium concentration occurred between 2 
Discussion
The results of this study have shown that the Ventstream nebuliser delivery system produced a twofold increase in delivery of salbutamol to the lung with associated greater systemic ,2 responses. There were also differences in the dose-response relationship for FEV, and FEF>, , ,, and a greater PEFR response in terms of AUC, 24 liser. Furthermore, it is known that aerosol deposition within the lungs is dependent upon the size of the particles''"6 which varies according to the nebuliser type and the driving flow rate." C ) Indeed, it has been shown that particles smaller than 5 jim in diameter penetrate to the peripheral airways by virtue of the fact that they avoid deposition by impaction in the oropharynx or more central airways. ' In this respect the significantly greater percentage volume of particles with optimal diameter using the Ventstream, in combination with matching output to tidal volume, would tend to increase aerosol delivery to the alveoli which is known to be the major site for systemic absorption of salbutamol2. 2' The pharmacokinetic profile with a t,,iax of 5-10 minutes would also point towards systemic absorption occurring primarily from the lung rather than from the gut. Since the Ventstream does not increase oral deposition, the pharmacokinetic differences between the two nebulisers are therefore likely to be due to enhanced lung delivery and resulting increased bioavailability from the pulmonary vascular bed. It is also worth pointing out that the differences in particle size between the two nebulisers are thought to be due to their different internal design configurations, rather than the variation in airflow rates.
The enhanced systemic absorption of salbutamol with the Ventstream was associated with significantly greater extrapulmonary effects, although this was only seen at the 2 5 mg and 5 0 mg doses. This may be because the dose-response curve for the systemic effects becomes steep after the 1 25 mg dose, in contrast to the airways responses where the curve is relatively flat above this dose. This phenomenon has been described previously with metered dose aerosols evaluated over a similar dose range in asthmatic subjects.>'6 It is worth pointing out, however, that the mean maximal difference in delta response between the two nebulisers was only 0 21 mmol/1 for serum potassium concentration, 6 beats/min for heart rate, and 7 ms for Q-Tc; these differences are not likely to be of any relevance in terms of arrhythmogenic potential. This is also reflected in the magnitude of the absolute values (peak heart rate of 80 beats/min, nadir serum potassium concentration of [3] [4] [5] 
